|
|
Post by sla55 on Sept 5, 2017 8:03:18 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1039121Move Places MannKind in Area Rich with Biopharmaceutical Talent WESTLAKE VILLAGE, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park in Westlake Village, California. A photo accompanying this announcement is available at http: www.globenewswire.com/NewsRoom/AttachmentNg/1aeeebe3-558d-4ff0-910f-74247bf8c712MannKind, which is currently commercializing Afrezza® (insulin human) inhalation powder, moved from Valencia, California to be in an area well known for its biopharmaceutical talent and to offer greater convenience to its current employees. "MannKind is a dynamic, fast-moving and rapidly growing company. To fuel this growth, we need to add more talented people to our team. Moving to Westlake Village, which is proximal to a large number of companies in our industry, will help us attract top talent," said Michael Castagna, CEO, MannKind Corporation. "We're excited to be a member of the Westlake Village and greater Conejo Valley business community." MannKind has shattered the paradigm of diabetes management with Afrezza, the only inhalable insulin that improves glycemic control in adults with diabetes. MannKind also has additional therapeutic products in the pipeline using its dry powder formulation as a drug delivery platform.
|
|
|
|
Post by kbrion77 on Sept 5, 2017 8:10:36 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1039121Move Places MannKind in Area Rich with Biopharmaceutical Talent WESTLAKE VILLAGE, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park in Westlake Village, California. A photo accompanying this announcement is available at http: www.globenewswire.com/NewsRoom/AttachmentNg/1aeeebe3-558d-4ff0-910f-74247bf8c712MannKind, which is currently commercializing Afrezza® (insulin human) inhalation powder, moved from Valencia, California to be in an area well known for its biopharmaceutical talent and to offer greater convenience to its current employees. "MannKind is a dynamic, fast-moving and rapidly growing company. To fuel this growth, we need to add more talented people to our team. Moving to Westlake Village, which is proximal to a large number of companies in our industry, will help us attract top talent," said Michael Castagna, CEO, MannKind Corporation. "We're excited to be a member of the Westlake Village and greater Conejo Valley business community."
MannKind has shattered the paradigm of diabetes management with Afrezza, the only inhalable insulin that improves glycemic control in adults with diabetes. MannKind also has additional therapeutic products in the pipeline using its dry powder formulation as a drug delivery platform. I'd say that is a bit aggressive of a statement. |
|
|
|
Post by centralcoastinvestor on Sept 5, 2017 8:18:34 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1039121Move Places MannKind in Area Rich with Biopharmaceutical Talent WESTLAKE VILLAGE, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park in Westlake Village, California. A photo accompanying this announcement is available at http: www.globenewswire.com/NewsRoom/AttachmentNg/1aeeebe3-558d-4ff0-910f-74247bf8c712MannKind, which is currently commercializing Afrezza® (insulin human) inhalation powder, moved from Valencia, California to be in an area well known for its biopharmaceutical talent and to offer greater convenience to its current employees. "MannKind is a dynamic, fast-moving and rapidly growing company. To fuel this growth, we need to add more talented people to our team. Moving to Westlake Village, which is proximal to a large number of companies in our industry, will help us attract top talent," said Michael Castagna, CEO, MannKind Corporation. "We're excited to be a member of the Westlake Village and greater Conejo Valley business community."
MannKind has shattered the paradigm of diabetes management with Afrezza, the only inhalable insulin that improves glycemic control in adults with diabetes. MannKind also has additional therapeutic products in the pipeline using its dry powder formulation as a drug delivery platform. I'd say that is a bit aggressive of a statement. Yep. It's sounds like it's coming from a CEO in a company about to go bankrupt. Not. This is the kind of statement and go get it attitude in my opinion that we always wanted to see in our CEO. Mike needs to continue to be aggressive. It's one sentence statements like this that get picked up by other news organizations. |
|
|
|
Post by therealisaching on Sept 5, 2017 8:19:27 GMT -5
investors.mannkindcorp.com/releasedetail.cfm?ReleaseID=1039121Move Places MannKind in Area Rich with Biopharmaceutical Talent WESTLAKE VILLAGE, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced today the company has fully relocated its corporate headquarters to a 12,596-square-foot location in the Westlake Landmark office park in Westlake Village, California. A photo accompanying this announcement is available at http: www.globenewswire.com/NewsRoom/AttachmentNg/1aeeebe3-558d-4ff0-910f-74247bf8c712MannKind, which is currently commercializing Afrezza® (insulin human) inhalation powder, moved from Valencia, California to be in an area well known for its biopharmaceutical talent and to offer greater convenience to its current employees. "MannKind is a dynamic, fast-moving and rapidly growing company. To fuel this growth, we need to add more talented people to our team. Moving to Westlake Village, which is proximal to a large number of companies in our industry, will help us attract top talent," said Michael Castagna, CEO, MannKind Corporation. "We're excited to be a member of the Westlake Village and greater Conejo Valley business community."
MannKind has shattered the paradigm of diabetes management with Afrezza, the only inhalable insulin that improves glycemic control in adults with diabetes. MannKind also has additional therapeutic products in the pipeline using its dry powder formulation as a drug delivery platform. I'd say that is a bit aggressive of a statement. I like it. I'm not sure I've heard them say " the only inhalable insulin that improves glycemic control in adults with diabetes" in a pr before. |
|
|
|
Post by kite on Sept 5, 2017 8:19:45 GMT -5
I'd say that is a bit aggressive of a statement. Yep. It's sounds like it's coming from a CEO in a company about to go bankrupt. Not. This is the kind of statement and go get it attitude in my opinion that we always wanted to see in our CEO. Mike needs to continue to be aggressive. It's one sentence statements like this that get picked up by other news organizations. Agreed! |
|
|
|
Post by #NoMoreNeedles on Sept 5, 2017 9:51:51 GMT -5
The PR is great for SEO  |
|
